A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE III DI CONFRONTO TRA BORTEZOMIB, CICLOFOSFAMIDE E DESAMETASONE RISPETTO A LENALIDOMIDE, CICLOFOSFAMIDE E DESAMETASONE IN PAZIENTI CON MIELOMA MULTIPLO IN PRIMA RICADUTA.

Trial Profile

A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE III DI CONFRONTO TRA BORTEZOMIB, CICLOFOSFAMIDE E DESAMETASONE RISPETTO A LENALIDOMIDE, CICLOFOSFAMIDE E DESAMETASONE IN PAZIENTI CON MIELOMA MULTIPLO IN PRIMA RICADUTA.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MM-Rel
  • Most Recent Events

    • 10 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top